Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors

Seminars in Oncology

Volumn 38, Issue 1 SUPPL., 2011, Pages

  Demetri, George D ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; MASITINIB; NILOTINIB; SORAFENIB; SUNITINIB;

ARTICLE; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; ERYTHEMA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IC 50; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEIOTROPY; PRIORITY JOURNAL; RASH;

CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 79952763618     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.01.018     Document Type: Article

References (46)

1. N. Koon, R. Schneider-Stock, and M. Sarlomo-Rikala Molecular targets for tumour progression in gastrointestinal stromal tumours Gut 53 2004 235 240 (Pubitemid 38125511)
2. E. Zwick, J. Bange, and A. Ullrich Receptor tyrosine kinase signalling as a target for cancer intervention strategies Endocr Relat Cancer 8 2001 161 173 (Pubitemid 32947638)
3. N.P. Agaram, G.C. Wong, and T. Guo Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors Genes Chromosomes Cancer 47 2008 853 859
4. C.R. Antonescu Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas Mod Pathol 21 Suppl 2 2008 S31 S36
5. H. Joensuu Gastrointestinal stromal tumor (GIST) Ann Oncol 17 Suppl 10 2006 x280 x286
6. NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma Vol 2. 2010 http://www.nccn.org/professionals/physician-gls/f-guidelines.asp Accessed August 22, 2010
7. C.D. Blanke, G.D. Demetri, and M. von Mehren Léong-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT J Clin Oncol 26 2008 620 625 (Pubitemid 351264357)
8. C.D. Blanke, C. Rankin, and G.D. Demetri Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the Kit receptor tyrosine kinase: S0033 J Clin Oncol 26 2008 626 632 (Pubitemid 351264358)
9. P.G. Casali, and J.Y. Blay Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 Suppl 5 2010 v98 v102
10. G.D. Demetri, M. von Mehren, and C.D. Blanke Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 2002 472 480 (Pubitemid 34879334)
11. C.R. Antonescu, P. Besmer, and T. Guo Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation Clin Cancer Res 11 2005 4182 4190 (Pubitemid 40791584)
12. H. Prenen, J. Cools, and N. Mentens Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate Clin Cancer Res 12 2006 2622 2627
13. G.D. Demetri, A.T. van Oosterom, and C.R. Garrett Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 2006 1329 1338 (Pubitemid 44528723)
14. V.L. Goodman, E.P. Rock, and R. Dagher Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma Clin Cancer Res 13 2007 1367 1373 (Pubitemid 46450424)
15. M.E. Lacouture, L.M. Reilly, P. Gerami, and J. Guitart Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib Ann Oncol 19 2008 1955 1961
16. L. Wood Managing the side effects of sorafenib and sunitinib Commun Oncol 3 2006 558 562 (Pubitemid 44785334)
17. E. Weisberg, P.W. Manley, and W. Breitenstein Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 7 2005 129 141 (Pubitemid 40248339)
18. G.D. Demetri, P.G. Casali, and J.Y. Blay A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors Clin Cancer Res 15 2009 5910 5916
19. M. Montemurro, P. Schoffski, and P. Reichardt Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib Eur J Cancer 45 2009 2293 2297
20. P. Reichardt, J. Blay, and H. Gelderblom Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): first results from ENEST g3 J Clin Oncol 28 2010 10017
21. G. Saglio, D.W. Kim, and S. Issaragrisil Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia N Engl J Med 362 2010 2251 2259
22. M. Bantscheff, D. Eberhard, and Y. Abraham Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors Nat Biotechnol 25 2007 1035 1044 (Pubitemid 47517638)
23. M. Deininger, E. Buchdunger, and B.J. Druker The development of imatinib as a therapeutic agent for chronic myeloid leukemia Blood 105 2005 2640 2653 (Pubitemid 40446252)
24. D.B. Mendel, A.D. Laird, and X. Xin In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 2003 327 337 (Pubitemid 36109749)
25. J.C. Soria, C. Massard, and N. Magne Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers Eur J Cancer 45 2009 2333 2341
26. S.M. Wilhelm, C. Carter, and L. Tang BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109 (Pubitemid 39331023)
27. PubChem http://pubchem.ncbi.nlm.NIH.gov/ 2010 Accessed July 27, 2010
28. K.S. Gajiwala, J.C. Wu, and J. Christensen KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients Proc Natl Acad Sci U S A 106 2009 1542 1547
29. C.D. Mol, D. Fabbro, and D.J. Hosfield Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors Curr Opin Drug Discov Dev 7 2004 639 648 (Pubitemid 39329866)
30. M.W. Karaman, S. Herrgard, and D.K. Treiber A quantitative analysis of kinase inhibitor selectivity Nat Biotechnol 26 2008 127 132
31. M.C. Heinrich, R.G. Maki, and C.L. Corless Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor J Clin Oncol 26 2008 5352 5359
32. E. Buchdunger, C.L. Cioffi, and N. Law Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors J Pharmacol Exp Ther 295 2000 139 145
33. B.J. Druker, S. Tamura, and E. Buchdunger Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 1996 561 566
34. E. Weisberg, P. Manley, and J. Mestan AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL Br J Cancer 94 2006 1765 1769 (Pubitemid 43882564)
35. A.M. O'Farrell, T.J. Abrams, and H.A. Yuen SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo Blood 101 2003 3597 3605 (Pubitemid 36857948)
36. R. Kumar, M.C. Crouthamel, and D.H. Rominger Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors Br J Cancer 101 2009 1717 1723
37. F. Bertucci, A. Goncalves, and G. Monges Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour Oncol Rep 16 2006 97 101
38. L.L. Chen, J.C. Trent, and E.F. Wu A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors Cancer Res 64 2004 5913 5919 (Pubitemid 39129383)
39. E. Tamborini, L. Bonadiman, and A. Greco A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient Gastroenterology 127 2004 294 299 (Pubitemid 38962296)
40. T. Wakai, T. Kanda, and S. Hirota Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation Br J Cancer 90 2004 2059 2061 (Pubitemid 38869705)
41. E. Wardelmann, S. Merkelbach-Bruse, and K. Pauls Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate Clin Cancer Res 12 2006 1743 1749
42. J.F. Lyons, S. Wilhelm, B. Hibner, and G. Bollag Discovery of a novel Raf kinase inhibitor Endocr Relat Cancer 8 2001 219 225 (Pubitemid 32947644)
43. S. Wilhelm, and D.S. Chien BAY 43-9006: preclinical data Curr Pharm Des 8 2002 2255 2257 (Pubitemid 35189898)
44. T. Guo, N.P. Agaram, and G.C. Wong Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor Clin Cancer Res 13 2007 4874 4881 (Pubitemid 47294795)
45. G.D. Demetri, R.P. Lo, and I.R. MacPherson Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors Clin Cancer Res 15 2009 6232 6240
46. A. Le Cesne, J.Y. Blay, and B.N. Bui Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST) Eur J Cancer 46 2010 1344 1351